Insmed Incorporated (FRA:IM8N)

Market Cap	28.16B +130.7%
Revenue (ttm)	381.00M +30.3%
Net Income	-1.01B
EPS	-5.30
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	75
Open	134.00
Previous Close	133.00
Day's Range	134.00 - 134.00
52-Week Range	58.00 - 185.00
Beta	n/a
RSI	33.21
Earnings Date	Feb 27, 2026

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 1,271
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IM8N

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD